BACKGROUND: The follow-up of patients with cutaneous melanoma is controversial. Current recommendations suggest routine history and physical examination every 3 to 6 months for the first 3 years and correlate studies including laboratory tests and radiographic imaging. However, the utility of these recommendations are unclear. The purpose of this study was to determine the impact of routine imaging on the method of detection of first recurrence in patients with stage II and sentinel lymph node-positive stage III melanoma. METHODS: We analyzed a prospective database of all cutaneous melanoma patients treated at our institution from 1997 to 2005 who had at least 2 years of follow-up. The method of detection of initial recurrence was analyzed. RESULTS: One hundred eighteen patients with stage II (n = 83) or III (n = 35) melanoma who were followed for at least 2 years were identified. Forty-three of these patients developed recurrence (median time to recurrence, 14 months). Site of first recurrence was as follows: 4 local, 17 in transit, 7 regional lymph node, and 15 distant. Twenty-nine recurrences (67%) were either patient detected or symptomatic. Eleven (26%) were detected by the physician at routine follow-up. Only three (7%) were identified by imaging (two chest X-ray and one brain magnetic resonance imaging) in an otherwise asymptomatic patient. CONCLUSIONS: Two-thirds of all initial recurrences of cutaneous melanoma were either detected by a patient or were symptomatic, with most of the remainder detected during routine physical examination. Routine imaging added little value in the detection of initial recurrence.
BACKGROUND: The follow-up of patients with cutaneous melanoma is controversial. Current recommendations suggest routine history and physical examination every 3 to 6 months for the first 3 years and correlate studies including laboratory tests and radiographic imaging. However, the utility of these recommendations are unclear. The purpose of this study was to determine the impact of routine imaging on the method of detection of first recurrence in patients with stage II and sentinel lymph node-positive stage III melanoma. METHODS: We analyzed a prospective database of all cutaneous melanomapatients treated at our institution from 1997 to 2005 who had at least 2 years of follow-up. The method of detection of initial recurrence was analyzed. RESULTS: One hundred eighteen patients with stage II (n = 83) or III (n = 35) melanoma who were followed for at least 2 years were identified. Forty-three of these patients developed recurrence (median time to recurrence, 14 months). Site of first recurrence was as follows: 4 local, 17 in transit, 7 regional lymph node, and 15 distant. Twenty-nine recurrences (67%) were either patient detected or symptomatic. Eleven (26%) were detected by the physician at routine follow-up. Only three (7%) were identified by imaging (two chest X-ray and one brain magnetic resonance imaging) in an otherwise asymptomatic patient. CONCLUSIONS: Two-thirds of all initial recurrences of cutaneous melanoma were either detected by a patient or were symptomatic, with most of the remainder detected during routine physical examination. Routine imaging added little value in the detection of initial recurrence.
Authors: Jerod L Stapleton; Rob Turrisi; Kimberly A Mallett; June K Robinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Shoshanna N Zucker; Jennifer Zirnheld; Archis Bagati; Thomas M DiSanto; Benjamin Des Soye; Joseph A Wawrzyniak; Kasra Etemadi; Mikhail Nikiforov; Ronald Berezney Journal: Cancer Biol Ther Date: 2012-08-16 Impact factor: 4.742
Authors: Hadeel Halalsheh; Sue C Kaste; Fariba Navid; Armita Bahrami; Barry L Shulkin; Bhaskar Rao; Michelle Kunkel; Nathan Artz; Alberto Pappo Journal: Pediatr Blood Cancer Date: 2018-08-19 Impact factor: 3.167
Authors: Erin R DeRose; Alexander Pleet; Wei Wang; Virginia J Seery; Mee Young Lee; Sharon Renzi; Ryan J Sullivan; Michael B Atkins Journal: Melanoma Res Date: 2011-08 Impact factor: 3.599
Authors: Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier Journal: Melanoma Res Date: 2012-10 Impact factor: 3.599